Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 11:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 271 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ritalin Clear all
Completed Phase 4 Interventional Results available

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

NCT00776009
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long-Duration Stimulant Treatment Study of ADHD in Young Children

NCT00257725
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
B-MPH
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
4 Years to 5 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 4, 2026, 11:13 AM EDT
Recruiting Phase 4 Interventional

Medication Treatment of ADHD in Pediatric Epilepsy

NCT07594652
View directory record Official record
Conditions
ADHD - Attention Deficit Disorder With Hyperactivity
Interventions
methylphenidate hydrochloride (Jornay PM)
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
6 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

NCT02255513
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Newport Beach, California • Marshfield, Massachusetts • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 4, 2026, 11:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD

NCT04577417
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
Interventions
ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 4, 2026, 11:13 AM EDT
Completed No phase listed Observational

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

NCT04132557
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
430,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 4, 2026, 11:13 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer

NCT03772834
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Exercise Intervention, Methylphenidate, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Stretching
Behavioral · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Methylphenidate and a Nursing Telephone Intervention for Fatigue

NCT00424099
View directory record Official record
Conditions
Advanced Cancer, Fatigue
Interventions
Methylphenidate, Nursing Telephone Intervention, Placebo, Non NTI
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Phase 3 Interventional

Further Studies of Attention Deficit Disorder - Residual Type (RT)

NCT00693212
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
methylphenidate, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1986 – 1994
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

NCT01338818
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Ritalin LA (methylphenidate hydrochloride extended release)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 4, 2026, 11:13 AM EDT
Withdrawn Early Phase 1 Interventional

Dopamine Rhythms in Health and Addiction

NCT02233829
View directory record Official record
Conditions
Cocaine Abuse
Interventions
Brain Dopamine Reactivity, Brain Dopamine Receptor
Drug · Radiation
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 4, 2026, 11:13 AM EDT
Active, not recruiting Phase 4 Interventional

Single and Combined Effects of Behavioral, Academic, and Medication Treatments for ADHD in the Classroom

NCT05469386
View directory record Official record
Conditions
ADHD
Interventions
Methylphenidate Hydrochloride ER, Behavioral classroom, Placebo, General Classroom, Academic Accommodations
Drug · Behavioral
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Miami, Florida • Amherst, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis

NCT03185065
View directory record Official record
Conditions
Fatigue in Multiple Sclerosis
Interventions
Amantadine, Modafinil, Methylphenidate, Placebos
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Phase 3 Interventional

Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)

NCT00018863
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
3 Years to 5 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Methylphenidate to Improve Balance and Walking in MS

NCT01896700
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Phase 4 Interventional Results available

Large-scale Brain Organization During Cognitive Control in ADHD

NCT04349917
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
8 Years to 12 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety

NCT02021214
View directory record Official record
Conditions
PTSD
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Phase 3 Interventional Results available

Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

NCT00501293
View directory record Official record
Conditions
ADHD
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
13 Years to 17 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
32
States / cities
Scottsdale, Arizona • Lafayette, California • Wildomar, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults

NCT00302354
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OROS methylphenidate HCl, SODAS methylphenidate HCl
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Phase 4 Interventional

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

NCT00228046
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Divalproex Sodium, Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts, Family Counseling, Behavior Management Training with Parents
Drug · Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Hyde Park, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Phase 3 Interventional Results available

Apathy in Dementia Methylphenidate Trial 2

NCT02346201
View directory record Official record
Conditions
Apathy, Alzheimer's Disease
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 4, 2026, 11:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Family Risk Analysis of Substance Use in Attention Deficit Hyperactivity Disorder (ADHD) Youth Treated With Concerta

NCT00181792
View directory record Official record
Conditions
ADHD, Smoking
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

NCT01993108
View directory record Official record
Conditions
Healthy, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Naltrexone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Sep 4, 2026, 11:13 AM EDT
Completed Not applicable Interventional Results available

Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study

NCT01533493
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)
Interventions
Placebo, Memantine Hydrochloride, OROS-Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 4, 2026, 11:13 AM EDT